Entrance to IPC Sustainability Index and MSCI Index

Transcription

1

2

3 Acquisition of 2 packages of brands in our international operations Entrance to IPC Sustainability Index and MSCI Index Changed Business Model to OTC/PC Founded as an infomercial marketing company Expanded management team Organic growth through brand and product development Acquisition of the brands: Fermodyl, Zan Zusi, Altiva, Amara, Larizá, Bioskin and XL-3 in Mexico, Babysan and Piecidex in Argentina and Dermaglós in Brazil Acquisition of the brands Nasalub, Micotex, Ossart, English Leather, Galaflex, Affair and Santé Launch of Primer Nivel, Genomma Lab s Branded Generics Line Expanded product portfolio through development of new products and line extensions Acquisition of Marzam Acquisition of Tafirol in Argentina, and Losec and package of OTC brands in Mexico Acquisition of the brands Vanart, Pomada de la Campana, Wildroot, Alert and Nórdiko With the launch of operations in Brazil and USA, Genomma has operations in 14 countries Acquisitions of Medicinas y Medicamentos Nacionales, Jockey Club, Flor de Naranja Sanborns, Teatrical and Henna Egipcia Performed its IPO in the Mexican Stock Market Nexxus Capital invested 30% of Equity

4

5

6 INNOVATION & DEVELOPMENT (Product Selection) OUTSOURCED MANUFACTURING QUALITY ASSURANCE SALES DISTRIBUTION MARKETING & BRANDING Best formulation and presentation Performance Analysis Impressively short lead time from an idea generation to new product launches and line extensions. Rapid and effective reaction to competitive challenges Pillars

7 Offers branded OTC pharmaceuticals in variety of forms - Inhibitors of gastric secretions - Hemorrhoid treatment - Anti-flu - Anti-acne Offers over 100 SKU s under the brand Primer Nivel Por Tu Salud - Anti-rheumatics - Anti-ulcer drugs - Anti-histamines - Anti-micotics Focuses on topical dermatological, facial and hair treatments and other categories - Varicose vein treatment - Scar removal - Face and body lotions - Anti-fungals

8 Genomma's core asset is its portfolio of market leading brands. As of September 2014, the Company has a total of 91 brands. The following table shows the Company s top 25 brands for the last twelve months as of September 2014, which represented 82.1% of Total Sales. Anti-scar, Anti-wrinkle Anti-acne Spider Vein Treatment Hair Care Baldness Treatment Anti-flu Anti-micotic Anti-flu Anti-dandruff Shampoo Vitamins Shampoo Hemorrhoid Treatment Cervical Infections Treatment Sexual Protection and Enhancement Colitis Treatment Osteoarthritis Treatment Athlete s Foot Treatment Cough Syrup Analgesic Gastritis Treatment Weight Control Treatment Pain Relief Shampoo Headache Treatment Hair Care

9 Demand for our products is mainly generated through advertising. We have a directed advertising strategy, based on metric analyses of our clients and the market. We monitor such information weekly, which allows us to have a quick response to changes in competition and consumer s preferences.

10

11 (For the last twelve months, as of September 2014) Genomma Lab Bayer Boehringer Sanofi Aventis Shering Plough Pisa Reckitt Benckiser Novartis Wyeth Johnson Johnson Source: IMS Health.

12 Source: Company data and IMS Health.

13 Source: Company data and IMS Health..

14 OTC Over the Counter Pharma OTC and Generics PC Personal Care Pharma PC 1. Brazil 2. Argentina 3. USA 4. Colombia 5. Chile 6. Peru 7. Ecuador OTC PC *According to IMS.

15 *As of September 2014 (LTM)

16 Brands: 91 Brands: 19 Brands: 13 Bolivia Chile Costa Rica Dominican Republic Ecuador El Salvador Guatemala Honduras Nicaragua Panama Paraguay Peru Uruguay Brands: 26 Brands: 12 Brands: 25

17 Innovation & Development Broad Distribution Line Extensions Brand Development International Expansion Entrance to new segments Formula Improvement Revitalize Acquired Brands Implement Marketing Capabilities

18 Q14 LTM *CAGR from 2008 to 2013

19 Nasal Hygiene For adults For children Nasalub Max Vitamins Energetic beverage with vitamins Vitamins for children

20 Osteoarthritis treatment for diabetics X-Ray with added Calcium and Vitamin D Osteoarthritis treatment Joint pain relief

21

22 Q13 3Q14 YoY Growth: 9.5% 3Q14 3Q13 Pharma* PC Total 3Q14 Pharma* PC Total 3Q13 %Var Mexico 1, , , , % International , , % TOTAL 1, , , , , , %

23 Q13 3Q14 3,500 3,000 2,500 2,000 1,500 1, YoY Growth: 6.8% 50.0% 40.0% 30.0% 20.0% 10.0% - 0.0% EBITDA EBITDA MARGIN

24 1Q12 2Q12 3Q12 4Q12 1Q13 2Q13 3Q13 4Q13 1Q14 2Q14 3Q14

25 Q13 3Q14 YoY Growth: 1.3% NET INCOME AS % OF REVENUE

26 @